HSBC Holdings’s X4 Pharmaceuticals XFOR Stock Holding History

HSBC Holdings’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-664	Closed	-$4.7K	–	3270
2025 Q1	$4.7K	Buy	664 +6	+0.9%	+$83	﹤0.01%	3002
2024 Q4	$15.7K	Sell	658 -12	-2%	-$191	﹤0.01%	3059
2024 Q3	$13.4K	Buy	670 +199	+42%	+$4.15K	﹤0.01%	2959
2024 Q2	$8.83K	Hold	471	–	–	﹤0.01%	2899
2024 Q1	$19.6K	Buy	+471	New	+$13.1K	﹤0.01%	2995

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HSBC Holdings's XFOR Position: Q2 2025 in Review

HSBC Holdings sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 664 shares — an estimated $4.7K sold.

HSBC Holdings first reported a position in XFOR in Q1 2024 and held it in 5 quarters. The position peaked at $19.6K in Q1 2024. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

HSBC Holdings reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
HSBC Holdings sold 664 X4 Pharmaceuticals shares in Q2 2025, an estimated $4.7K.
HSBC Holdings first reported a position in X4 Pharmaceuticals in Q1 2024 and held it in 5 quarters.
HSBC Holdings's X4 Pharmaceuticals position peaked at $19.6K in Q1 2024.
51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on HSBC Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.